Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01174563
Other study ID # ML25200
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 23, 2011
Est. completion date December 20, 2016

Study information

Verified date September 2018
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This open-label, single arm study will assess the correlation between Tarceva (erlotinib)-induced rash and efficacy in participants with inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) receiving first-line therapy for advanced disease. Participants will receive Tarceva at a dose of 150 mg daily orally, with dose adjustments according to protocol depending on toxicity. Anticipated time on study treatment is until disease progression, unacceptable toxicity, or withdrawal due to any reason.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 20, 2016
Est. primary completion date December 20, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult participants, >/= 18 years of age

- Inoperable, locally advanced, recurrent or metastatic (Stage IIIB or IV) non-small cell lung cancer (NSCLC)

- Presence of epidermal growth factor receptor (EGFR) mutations

- Previously untreated with any systemic anti-neoplastic therapy for advanced disease

- Last dose of a prior systemic anti-neoplastic therapy for early-stage disease >/= 4 weeks before study start, and patient recovered from acute toxicities of any previous therapy

- A life expectancy of at least 12 weeks

- Able to comply with the study and its follow-up procedures

- Female participants had to be postmenopausal (24 months of amenorrhea), surgically sterile or agree to use a physical method of contraception. Male participants had to be surgically sterile or agree to use a barrier method of contraception. Women with an intact uterus (unless amenorrhoeic for the last 24 months) had to have a negative pregnancy test (urine or serum) within 3 days prior to erlotinib treatment initiation in the study. Male and female participants had to use effective contraception during the study and for a period of 90 days following the last administration of erlotinib. Acceptable methods of contraception included an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms)

Exclusion Criteria:

- Pregnant or breast feeding women

- Granulocyte count <1.5 x 109/L and platelet count <100*10^9/L

- Serum bilirubin >1.5 upper limit of normal (ULN)

- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2 * ULN (or >5 * ULN if clearly attributable to liver metastasis)

- Serum creatinine >1.5 ULN or creatinine clearance <60 mL/min

- Known allergy or other adverse reaction to study drug or any other related compound

- Any significant unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, hepatic, renal or metabolic disease)

- Prior systemic anti-neoplastic therapy with HER1/EGFR inhibitors (as small molecule or monoclonal antibody therapy)

- Newly diagnosed or not yet definitively treated (i.e. stable disease >/= 2 months) CNS metastases or spinal cord compression

- Any significant ophthalmological abnormality, especially those likely to increase the risk of corneal epithelial lesions (the use of contact lenses is not recommended during the study)

- Participants who could not take oral medication, who required intravenous alimentation, had had prior surgical procedures affecting absorption, or had active peptic ulcer disease

- Active cancer other than NSCLC, except for basal cell or squamous cell carcinomas of the skin that have been excised and cured

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
erlotinib [Tarceva]
150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol

Locations

Country Name City State
Israel Haemek Hospital; Oncology Afula
Israel Barzilai; Oncology Ashkelon
Israel Soroka Medical Center; Oncology Dept Beer Sheva
Israel Carmel Hospital; Oncology Unit Haifa
Israel Rambam Medical Center; Oncology Haifa
Israel Wolfson Hospital; Oncology Holon
Israel Hadassah Ein Karem Hospital; Oncology Dept Jerusalem
Israel Shaare Zedek Medical Center; Oncology Dept Jerusalem
Israel Meir Medical Center; Oncology Kfar-Saba
Israel Nahariya Hospital; Oncology Nahariya
Israel Chaim Sheba Medical Center; Oncology Dept Ramat Gan
Israel Kaplan Medical Center; Oncology Inst. Rehovot
Israel Ziv Medical Center; Oncology Department Sefad
Israel Sourasky / Ichilov Hospital; Oncology Department Tel Aviv
Israel Poria Hospital; Oncology Tiberias
Israel Assaf Harofeh; Oncology Zerifin

Sponsors (2)

Lead Sponsor Collaborator
Hoffmann-La Roche Clalit Health Services

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival (PFS) According to Grade of Rash PFS was defined as the time from start of treatment to the date of the first documented progression according to revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or the date of death for any reason in the absence of progressive disease (PD). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Day 1 of treatment period until disease progression or death (approximately up to 67 months)
Secondary Percentage of Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4 Day 1 of treatment period until disease progression or death (approximately up to 67 months)
Secondary Progression-Free Survival (PFS) in Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4 PFS was defined as the time from start of treatment to the date of the first documented progression according to revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or the date of death for any reason in the absence of progressive disease (PD). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. Day 1 of treatment period until disease progression or death (approximately up to 67 months)
See also
  Status Clinical Trial Phase
Completed NCT02264990 - Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers Phase 3
Completed NCT01328951 - A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy Phase 3
Completed NCT01664533 - An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy N/A
Completed NCT00988936 - Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug Phase 2
Completed NCT00976456 - Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer Phase 3
Completed NCT02596958 - Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants N/A
Completed NCT00974584 - A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT00451906 - A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Phase 4
Completed NCT03329911 - A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer Phase 3
Not yet recruiting NCT03671538 - Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin N/A
Completed NCT01512420 - An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT) N/A
Completed NCT01185847 - A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Phase 2
Completed NCT01204697 - A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) Phase 2
Terminated NCT00760929 - A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). Phase 2
Withdrawn NCT03319316 - Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) Phase 2
Recruiting NCT06334757 - Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure Phase 2
Recruiting NCT06396065 - Phase III Study of AK112 for NSCLC Patients Phase 3
Completed NCT01763671 - Paclitaxel-bevacizumab in Advanced Lung Cancer Phase 3
Terminated NCT01990261 - A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment. N/A
Completed NCT01836133 - An Observational Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT) N/A